At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm.
Questions
1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04)
2. What are the major treatment challenges in sarcomatoid RCC? (0:54)
3. Why is sarcomatoid RCC particularly responsive to immune checkpoint blockade? (1:40)
4. What is the impact on patient survival? (2:45)
5. What further data are needed for checkpoint inhibitors to become the standard of care in sarcomatoid RCC? (3:11)
Speaker disclosure: James Brugarolas has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
